Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02800928 · ClinicalTrials.gov registry record · Phase 2
Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT02800928 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 17 participants.
The verdict
NCT02800928, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Stress-precipitated Smoking Behavior.
Interventions
- DRUG Placebo
- DRUG CERC-501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2018-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02800928
The ClinicalTrials.gov registry entry for NCT02800928 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02800928 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02800928 about?
NCT02800928 is a clinical study titled "Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?". A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Stress-precipitated Smoking Behavior.
What is the current status of trial NCT02800928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2016-06-30. Estimated completion is 2018-01-02.
What interventions are being tested in trial NCT02800928?
The interventions under investigation include: Placebo (DRUG), CERC-501 (DRUG).
Who is sponsoring clinical trial NCT02800928?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.